GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma
August 21, 2026 | Friday | News
Singapore’s HSA approved two Blenrep combination regimens following Phase III DREAMM-7 and DREAMM-8 data demonstrating improvements in progression-free survival.
GSK Singapore has received Health Sciences Authority approval for Blenrep, or belantamab mafodotin, in two combination regimens for adults with relapsed or refractory multiple myeloma.
Blenrep in combination with bortezomib and dexamethasone has been approved for patients who have received at least one prior therapy.
The therapy has also been approved in combination with pomalidomide and dexamethasone for patients who have received at least one prior therapy including lenalidomide.
Blenrep is an antibody-drug conjugate targeting B-cell maturation antigen, or BCMA.
The approvals are supported by data from the Phase III DREAMM-7 and DREAMM-8 trials.
Both studies demonstrated statistically significant and clinically meaningful improvements in progression-free survival for Blenrep combinations compared with triplet standard-of-care regimens.
DREAMM-7 also demonstrated an overall survival benefit compared with a daratumumab-based triplet regimen.
The safety and tolerability profiles of the combinations were broadly consistent with the known profiles of the individual treatments.
“Today’s approval of Blenrep combinations is a redefining moment for patients with relapsed or refractory multiple myeloma in Singapore,” said Aldo Amador Navarro Rojas, Country Medical Director Singapore at GSK.
“While significant progress has been made in the management of multiple myeloma, most patients will eventually experience relapse, highlighting the need for new treatment options that can help extend remission, prolong survival and support quality of life.”
Approximately 100 to 120 people are diagnosed with multiple myeloma each year in Singapore.
GSK said the combinations provide an additional BCMA-targeted treatment option that can be administered in outpatient settings.
The Singapore approval expands the treatment options available from first relapse onward for patients with multiple myeloma and follows the broader global development of belantamab mafodotin combinations through the DREAMM clinical programme.